{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:30:01Z","timestamp":1792053001772,"version":"4.4.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Oryn Therapeutics, LLC"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:p>\n            Severe illness caused by coronavirus disease 2019 (COVID-19) is characterized by an overexuberant inflammatory response resulting in acute respiratory distress syndrome (ARDS) and progressive respiratory failure (\n            <jats:xref ref-type=\"bibr\">1<\/jats:xref>\n            ). Rhesus theta (\u03b8) defensin-1 (RTD-1) is a macrocyclic host defense peptide exhibiting antimicrobial and immunomodulatory activities.\n          <\/jats:p>","DOI":"10.1128\/aac.02125-21","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T20:16:47Z","timestamp":1642537007000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical Pharmacokinetics and Safety of Intravenous RTD-1"],"prefix":"10.1128","volume":"66","author":[{"given":"A. Young J.","family":"Park","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dat Q.","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA"},{"name":"Oryn Therapeutics, Vacaville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-4917","authenticated-orcid":true,"given":"Justin B.","family":"Schaal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Selsted","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA"},{"name":"Oryn Therapeutics, Vacaville, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-3310","authenticated-orcid":true,"given":"Paul M.","family":"Beringer","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0968-3"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01363-09"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2016-0428OC"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108393"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1001-0939.2020.03.013"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05991-x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01090-07"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0009737"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00154-17"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53402-z"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.3A0315-102R"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.000793"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0051337"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1152\/physiolgenomics.00066.2019"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187868"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.etp.2005.10.002"},{"key":"e_1_3_2_20_2","volume-title":"Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.","author":"FDA","year":"2005","unstructured":"FDA. 2005. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3089.2004.00186.x"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0191-1"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0331-4"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0917-z"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-010-0098-6"},{"key":"e_1_3_2_26_2","first-page":"582","article-title":"Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues","volume":"28","author":"Tanaka C","year":"2000","unstructured":"Tanaka C, Kawai R, Rowland M. 2000. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab Dispos 28:582\u2013589.","journal-title":"Drug Metab Dispos"},{"key":"e_1_3_2_27_2","first-page":"520","article-title":"Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats","volume":"283","author":"Kato M","year":"1997","unstructured":"Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. 1997. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520\u2013527.","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9687-3"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0079-0"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498254.2011.598582"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3109\/00498259609052491"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/a:1015836720294"},{"key":"e_1_3_2_33_2","volume-title":"Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.","author":"FDA","year":"2005","unstructured":"FDA. 2005. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Food and Drug Administration, Rockville, MD."},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03190588"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18786-x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1583OC"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/009286159502900324"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061514"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02125-21","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.02125-21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T15:05:10Z","timestamp":1647356710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.02125-21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3,15]]}},"alternative-id":["10.1128\/aac.02125-21"],"URL":"https:\/\/doi.org\/10.1128\/aac.02125-21","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"assertion":[{"value":"2021-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02125-21"}}